HOME >> MEDICINE >> NEWS
Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial

Copenhagen, Denmark: Eagerly awaited results from the world's first head to head trial between the anti-cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol)[1] have shown that there was a better overall response rate and longer overall survival among breast cancer patients given docetaxel although docetaxel was associated with more severe side effects.

The new results were presented for the first time today (Wednesday 24 September) at ECCO 12 The European Cancer Conference taking place in Copenhagen.

Four hundred and forty nine women with advanced incurable breast cancer who had received previous treatment with an anthracycline-based chemotherapy were randomised into the Phase III trial from multiple centres across the USA between 1994 and 20012. Half were treated with paclitaxel and half were treated with docetaxel.

The trial's principal investigator, Professor Peter Ravdin, associate professor in the Department of Medicine at the University of Texas Health Science Center in San Antonio, told a news briefing that the women treated with docetaxel survived for a median 15.4 months compared with a median 12.7 months for the women who received paclitaxel.

There was an overall response rate of nearly a third among the docetaxel patients compared with a quarter for the paclitaxel patients. The median time before the breast cancer progressed (TTP) was 5.7 months for the docetaxel patients and 3.6 months for the paclitaxel patients. The results for overall survival and for TTP were statistically significantly superior for docetaxel and the overall response rate in favour of docetaxel approached statistical significance.

However, the women who received docetaxel did experience more severe side effects (grade 3/4 toxicities) with higher incidences of neutropenia (reduction in infection-fighting white blood cells), asthenia (loss of strength), infection, oedema (abnormal accumulation of fluid), mouth ulcers and neuromotor and n
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
45-3252-4163
Federation of European Cancer Societies
24-Sep-2003


Page: 1 2

Related medicine news :

1. Good intentions versus bad habits: Why the old ways win out
2. Normal aging versus Alzheimers disease and the potential for prevention
3. Regulatory T cells keep graft-versus-host disease in check
4. Study evaluates Abacavir, Lamivudine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz
5. U-M study finds new target in war against graft-versus-host disease
6. Weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) is safe and effective in patients with advanced lung cancer
7. International breast cancer prevention study launches in the United States and Canada
8. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Santa ... office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office features ... sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic ...
(Date:1/20/2017)... ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... homes across the world. Yisrayl says this generation is a time like no other and ... to the Bible. , Yisrayl says he does not want to sound like an old ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece of ... Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda Roberts, ... who had little knowledge of the female characters portrayed in the Holy Bible. ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story ... Sara Seymour, who lives in Lafayette, Indiana where she works in a daycare and ... and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
(Date:1/19/2017)... , Jan. 19, 2017 This report on ... and future scenario of the global market. Large number ... consumption. Severe chronic constipation is a major side effect ... laxatives. Hence, novel targeted therapy has been prescribed to ... launch of targeted medicines, and growing awareness about the ...
Breaking Medicine Technology:
Cached News: